Innate Pharma ADR Dossier
Qualitative Analysis
Business overview
Innate Pharma SA is a global, clinical-stage biotechnology company headquartered in Marseille, France, specializing in the development of first-in-class immunotherapies for cancer patients. The company leverages its deep expertise in natural killer (NK) cell biology and antibody engineering to build a highly differentiated pipeline. Its core therapeutic modalities include multi-specific NK cell engagers developed via its proprietary ANKET® platform, antibody-drug conjugates (ADCs), and monoclonal antibodies. Innate Pharma has established high-profile strategic collaborations with leading biopharmaceutical companies, notably AstraZeneca and Sanofi, to accelerate the development of its pipeline.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive corporate strategy focused on: (1) driving innovation with the first-in-class ANKET® NK-cell engager platform; (2) accelerating the development of differentiated Antibody-Drug Conjugates (ADCs), led by IPH4502; and (3) advancing late-stage assets (lacutamab and monalizumab) through strategic partnerships.
Expected impact: Redefine the immunotherapy landscape in oncology and autoimmune diseases while maximizing shareholder value through early clinical development of proprietary assets.
A strategic restructuring and workforce reduction plan designed to decrease overall staffing levels by approximately 30% to align the organization with its prioritized clinical assets.
Expected impact: Creation of a fit-for-purpose organizational structure, reduction of operational expenses, and extension of the cash runway to focus resources on high-value assets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Strengthens the ongoing development of multi-specific NK cell engagers using Innate's ANKET® platform, including the BCMA-targeting program (IPH6401/SAR'514) in autoimmune indications.
Terms: Sanofi made a €15 million equity investment in April 2025, acquiring 8,345,387 new ordinary shares at €1.7974 per share, representing a 9.05% ownership stake. Innate remains eligible for up to €1 billion in total development and commercial milestones plus royalties.
Underpins financial stability and late-stage pipeline progression through the co-development of monalizumab (Phase 3 PACIFIC-9 trial) and IPH5201 (Phase 2 MATISSE trial).
Terms: Innate receives cost-sharing for clinical trials and is eligible for future regulatory and commercial milestone payments, alongside royalties on potential net sales.